Universal Vision Biotechnology Co., Ltd. (3218.TWO)

TWD 172.5

(-6.5%)

Market Cap (In TWD)

14.61 Billion

Revenue (In TWD)

4.08 Billion

Net Income (In TWD)

1.04 Billion

Avg. Volume

159.31 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
200.5-307.0
PE
13.76
EPS
12.54
Beta Value
0.741
ISIN
TW0003218004
CUSIP
-
CIK
-
Shares
84724900.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Healthcare
CEO
Mr. Pi-Jung Lin
Employee Count
-
Website
https://www.uvb.com.tw/
Ipo Date
2007-12-31
Details
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Its clinic provides laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including a range of eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting. In addition, it engages in the provision of optometric, hospital management, and technical consultancy services; and sales and leasing of medical devices. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.